HOME - INVESTORS - REGULATED INFORMATION Regulated information 2020 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2021 09 NOVEMBER 2021 Voting rights on 31 October 2021 2021 10 31 Ipsen Voting rights 27 OCTOBER 2021 Ipsen Pledges Ambitious Action on Climate Change ENG — Press Release – Ipsen Pledge to Climate 27102021_FINAL 21 OCTOBER 2021 Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance YTD 2021 – Sales announcement YTD 2021 – Sales presentation 18 OCTOBER 2021 Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3 Ipsen – Accent collaboration – 18 October 2021 11 OCTOBER 2021 Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailled Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailled 11 OCTOBER 2021 Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International Ipsen – Appointment of Mari Scheiffele – 11 October 2021 08 OCTOBER 2021 Voting rights on 30 September 2021 2021 09 30 Ipsen Voting rights 18 SEPTEMBER 2021 ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncommon form of thyroid cancer Ipsen – ESMO 2021 – 18 February 2021 10 SEPTEMBER 2021 Voting rights on 31 August 2021 2021 08 31 Ipsen Voting rights 31 AUGUST 2021 Share buyback program – Ipsen reporting from 23 to 25 August 2021 Share buyback program – Ipsen reporting from 23 to 25 August 2021 – Detailled 17 AUGUST 2021 Share buyback program – Ipsen reporting from 16 to 20 August 2021 – Detailled Share buyback program – Ipsen reporting from 16 to 20 August 2021 – Detailled 17 AUGUST 2021 Share buyback program – Ipsen reporting from 09 to 13 August 2021 – Detailled Share buyback program – Ipsen reporting from 09 to 13 August 2021 – Detailled 13 AUGUST 2021 Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses Ipsen_Palovarotene NDA withdrawal_13 August 10 AUGUST 2021 Voting rights on 31 July 2021 03 AUGUST 2021 Share buyback program – Ipsen reporting from 26 to 30 July 2021 – Detailled Share buyback program – Ipsen reporting from 26 to 30 July 2021 – Detailled 03 AUGUST 2021 Ipsen publishes its 2021 half year financial report H1 2021 Half year financial report 02 AUGUST 2021 Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders Ipsen-Exicure collaboration-2 August 2021 29 JULY 2021 Ipsen delivers strong H1 2021 results and upgrades full-year guidance H1 2021 – Results announcement H1 2021 – Results presentation 27 JULY 2021 Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway Ipsen-BAKX collaboration-27 July 2021 27 JULY 2021 Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailled Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailled 20 JULY 2021 Share buyback program – Ipsen reporting from 12 july to 16 July 2021 – Aggregated Share buyback program – Ipsen reporting from 12 july to 16 July 2021 – Aggregated 13 JULY 2021 Share buyback program – Ipsen reporting from 05 to 09 July 2021 – Detailled Share buyback program – Ipsen reporting from 05 to 09 July 2021 – Detailled 09 JULY 2021 Voting rights on 30 June 2021 Ipsen – Voting rights – 2021 06 30 09 JULY 2021 Ipsen – Half year statement – 2021 06 30 IPSEN – 2021 06 30 – PR Half year statement S1 2021 06 JULY 2021 Share buyback program – Ipsen reporting from 28 june to 02 July 2021 Share buyback program – Ipsen reporting from 28 june to 02 July 2021 29 JUNE 2021 Share buyback program – Ipsen reporting from 21 june to 25 june 2021 Share buyback program – Ipsen reporting from 21 june to 25 June 2021 – Detailled 28 JUNE 2021 Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer Ipsen – Exelixis COSMIC-312 – 28 June 2021 22 JUNE 2021 Share buyback program – Ipsen reporting from 14 june to 18 June 2021 Share-buyback-program-Ipsen-reporting-from-14-june-to-18-June-2021 15 JUNE 2021 Share buyback program – Ipsen reporting from 7 june to 11 June 2021 Share buyback program – Ipsen reporting from 7 june to 11 June 2021 11 JUNE 2021 ISPRM 2021: New Ipsen analysis highlights potential treatment gap in adults living with spasticity Ipsen – ISPMR 2021 – 11 June 2021 10 JUNE 2021 Voting rights on 31 May 2021 Ipsen – Voting rights – 2021 05 31 08 JUNE 2021 Share buyback program – Ipsen reporting from 31 May to 4 June 2021 Share buyback program – Ipsen reporting from 31 May to 4 June 2021 07 JUNE 2021 Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021 Ipsen – Exelixis COSMIC-311 ASCO – 7 June 2021 02 JUNE 2021 Ipsen initiates a share buy-back program to cover its performance and employee share plans Ipsen initiates a share buy-back program to cover its performance and employee share plans 01 JUNE 2021 Ipsen announces the launch of an Employee Shareholding Plan Ipsen announces the launch of an Employee Shareholding Plan 28 MAY 2021 Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP) Ipsen – Palovarotene FDA acceptance – 28 May 2021 27 MAY 2021 Press release post SM Ipsen – Press release post SM – 27 May 2021 27 MAY 2021 Description of the share repurchase program Ipsen – Description of the share repurchase program – 27 May 2021 12 MAY 2021 Monthly information relative to the total number of voting rights and shares composing the share capital 2021 04 30 Ipsen Voting rights 11 MAY 2021 Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results 05 MAY 2021 Documents availbaility – Combined Shareholders’ Meeting of 27 May 2021 Documents availability – 2021 Ipsen Combined Shareholder’s Meeting 22 APRIL 2021 Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance Q1 2021 – Sales announcement Q1 2021 – Sales presentation 16 APRIL 2021 Combined Shareholders’ Meeting of 27 May 2021 Preliminary notice to the Meeting published at the BALO on 19 April 2021 – Translation for information Preliminary notice to the Meeting publsihed at the BALO on 19 April 2021 – French version only Report of the Board of Directors on the draft resolutions Universal-registration-document-2020 15 APRIL 2021 Ipsen publishes its 2020 Universal Registration Document Universal registration document 2020 – AMF deposit 09 APRIL 2021 Monthly information relative to the total number of voting rights and shares composing the share capital 2021 03 31 Ipsen Voting rights 31 MARCH 2021 European Commission approves Cabometyx® in combination with Opdivo® as a first-line treatment for patients living with advanced renal cell carcinoma Ipsen – Cabometyx Opdivo EMA Release – 31 March 2021 12 MARCH 2021 Monthly information relative to the total number of voting rights and shares composing the share capital 2021 02 28 Ipsen Voting rights 26 FEBRUARY 2021 Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma Ipsen – CHMP release – 26 February 2021 12 FEBRUARY 2021 Monthly information relative to the total number of voting rights and shares composing the share capital 2021 01 31 Ipsen Voting rights 11 FEBRUARY 2021 Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021 FY 2020 – Results announcement FY 2020 – Results presentation 08 FEBRUARY 2021 New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in combination with Opdivo® showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC Ipsen – ASCO GU 2021 – 8 February 2021 05 FEBRUARY 2021 Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021 Ipsen – ASCO GU 2021 – 5 February 2021 20 JANUARY 2021 Ipsen appoints Gwenan White as Executive Vice President, Communications and Public Affairs Ipsen – Gwenan White nomation – 20 January 2021 19 JANUARY 2021 Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF 20201231 – IPSEN – PR Half-year Statement S2 2020 15 JANUARY 2021 TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications Ipsen – TOXINS 2021 – 15 January 2021 12 JANUARY 2021 Monthly information relative to the total number of voting rights and shares composing the share capital 2020 12 31 Ipsen Voting rights Our company Our Science Our responsibility Patients Partnering Investors News Center Careers Terms & conditions Data privacy Cookie policy Global Privacy Policy © Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021 Your privacy is important to us By clicking “Accept All” , you agree to the storing of cookies on your device to enhance site navigation, measure site performance and show you personalized advertising. You can manage individual cookies preferences or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third-parties intervening on our website, please consult the Cookies Policy, available in the site footer. Cookies settings Reject all Accept all